title: Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma.
abstract: BACKGROUND
  The purpose of this study was to evaluate the toxicity and to determine adequate doses of combined concurrent therapy with carboplatin/UFT and radiotherapy. This regimen was designed for use on patients with complications of renal dysfunction, ischemic heart disease, or advanced age.
  
  
  METHODS
  Twenty-seven eligible patients with stages II-IV squamous cell carcinomas of the head and neck were treated with concurrent chemoradiotherapy. UFT was given orally at a dose of 300 mg/day daily. Carboplatin was given intravenously once a week at a dose of AUC 3-6. Radiotherapy was delivered in single daily fractions of 1.8-2.0 Gy, to a total dose of 66-70.2 Gy.
  
  
  RESULTS
  Unacceptable toxicity (neutropenic fever or mucotitis) was encountered with a carboplatin dose of AUC 6 and a UFT dose of 300 mg/day.
  
  
  CONCLUSIONS
  Combined radiotherapy and chemotherapy with carboplatin and UFT is a safe and well-tolerated regimen.
authors.affiliation: Department of Otorhinolaryngology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawai
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Idumi
authors.initials: I
authors.lastname: Mochimatsu
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000009:adverse effects; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D016190:Carboplatin